MLPSC Cell Therapy for Heart Failure Progression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for progressive heart failure, particularly in patients with Class II heart failure according to the New York Heart Association (NYHA) classification scale, are inadequate in preventing disease progression and reducing cardiac mortality and ischemic events.

Innovation Solution

Administering a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs) that induce new blood vessel formation and secrete protective factors for the myocardium, specifically for patients with elevated C-reactive protein (CRP) levels and Class II heart failure, to inhibit disease progression and reduce cardiac mortality.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for progressive heart failure, then treatment coverage is provided, but the treatments are inadequate in preventing disease progression and reducing cardiac mortality

Engineering Contradiction:

Improveeffectiveness in preventing disease progressionVSAvoidcardiac mortality and ischemic events

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses mesenchymal lineage precursor or stem cells (MLPSCs) as intermediary agents to deliver protective factors to the myocardium. These cells act as mediators that secrete trophic factors, growth factors, and anti-apoptotic proteins to protect cardiac tissue from damage and promote repair, thereby resolving the contradiction between providing treatment coverage and achieving effective prevention of disease progression and cardiac mortality

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The administered MLPSCs enable the heart tissue to repair itself by secreting protective factors and inducing new blood vessel formation. The cells integrate into the cardiac tissue and autonomously provide protective functions, reducing dependency on external continuous treatment and improving long-term reliability in preventing disease progression

Inventive Principle:

Principle #25Self-service

2Reliability

If cell therapy is administered to subjects with Class II heart failure, then disease progression is reduced and cardiac mortality is decreased, but the treatment is specifically targeted only to certain patient groups

Engineering Contradiction:

Improvereduction in cardiac death and ischemic eventsVSAvoidapplicability to different heart failure stages

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies cell therapy with specific characteristics tailored to Class II heart failure patients, who have mild to moderate symptoms and preserved ejection fraction. The MLPSCs are administered to provide localized protection to the myocardium in this specific patient population, optimizing the treatment effect for early-stage heart failure while avoiding potential harm in more advanced stages where the disease environment may be too compromised for cell therapy to be effective

Inventive Principle:

Principle #3Local quality

3Strength

If MLPSCs are administered to induce new blood vessel formation, then myocardial protection is enhanced, but the complexity of the treatment mechanism increases

Engineering Contradiction:

Improveprotection of at risk myocardiumVSAvoidcomplexity of cell therapy mechanism

Core Design Contradiction:

StrengthVSDevice complexity

Solution Approach 1:

The MLPSCs autonomously perform multiple protective functions including secreting trophic factors, inducing angiogenesis, reducing apoptosis, and modulating inflammation without requiring external control systems. The cells self-regulate their protective activities based on the local tissue environment, simplifying the overall treatment complexity while maintaining strong myocardial protection

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The administered MLPSCs provide multiple protective functions simultaneously - they secrete various growth factors, induce new blood vessel formation, protect against apoptosis, and reduce inflammation. This multi-functionality allows a single cell therapy intervention to address multiple pathological mechanisms underlying heart failure, enhancing myocardial protection without requiring multiple separate treatments

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method significantly reduces the risk of cardiac death, ischemic events, and progression to Class III heart failure, with a notable reduction in ischemic MACE by 60% and cardiac death by 33% in NYHA Class II patients with elevated CRP levels, indicating effective treatment and prevention of progressive heart failure.

Implementation Method 1

the cells induce new blood vessel formation in target tissue

Methodology Applied

Scientific EffectAngiogenesis:

Implementation Method 2

the cells secrete factors that protect at risk myocardium

Methodology Applied

Scientific EffectParacrine signaling:

Data Source

PatentUS20240041934A1Method of treating progressive heart failure in subjects with class ii heart failure

Publication Date: 2024.02.08 MESOBLAST INTERNATIONAL SARL

AI summary

The present disclosure relates to methods for treating and/or preventing progressive heart failure in subjects with earlier stages of heart failure. Such method may be used for treating or preventing progressive heart failure in subjects with Class II heart failure according to the New York Heart Association (NYHA) classification scale.